Tibotec

Tibotec is a pharmaceutical company that specializes in the development and commercialization of innovative drugs for infectious diseases such as HIV/AIDS and hepatitis C. The company is a subsidiary of Johnson & Johnson, a multinational corporation that manufactures medical devices, pharmaceuticals, and consumer packaged goods.

History[edit | edit source]

Tibotec was founded in 1994 in Belgium. The company's name is derived from the founders' names: Rudi Pauwels, Bart Stoffels, and Paul Stoffels. In 2002, Tibotec was acquired by Johnson & Johnson, and it has since become a global leader in the field of antiviral therapy.

Products[edit | edit source]

Tibotec is known for its innovative antiviral drugs, including:

Prezista (darunavir), a protease inhibitor used in the treatment of HIV.
Intelence (etravirine), a non-nucleoside reverse transcriptase inhibitor used in the treatment of HIV.
Edurant (rilpivirine), a non-nucleoside reverse transcriptase inhibitor used in the treatment of HIV.

Research and Development[edit | edit source]

Tibotec is committed to the research and development of new drugs for infectious diseases. The company's research focuses on the discovery of novel compounds that can inhibit the replication of viruses such as HIV and hepatitis C.